Skip to main content


Fig. 3 | Biomarker Research

Fig. 3

From: A preliminary analysis of interleukin-1 ligands as potential predictive biomarkers of response to cetuximab

Fig. 3

Tumor gene expression of IL-1 ligands predicts PFS in patients treated with cetuximab and chemotherapy. Comparison of pre-treatment tumor gene expression of IL1A (a) and IL1B (b) in HNSCC patients treated with first-line cetuximab-based chemotherapy separated into long progression free survival (PFS) (> 12 months, n = 14) and short PFS (< 5.6 months, n = 26)

Back to article page